Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 1, 2024
Finance
Public equity report: PIPEs, follow-ons for 11 biotechs add up to $3B+
Viking, Celldex, Janux offerings top list of follow-ons; Denali, Crinetics, Avidity among those raising PIPEs
BioCentury | Feb 21, 2024
Product Development
Clinical report: Latest setback in RIPK1 program for Denali, Sanofi
Plus: RAPT’s clinical hold, Tagrisso’s latest readout
BioCentury | Dec 7, 2023
Emerging Company Profile
GenFleet: building a fleet of first-in-class cancer and immune therapies
With its first regulatory submission filed in China, the biotech is setting its next sights on global first-in-class therapies
BioCentury | Jan 6, 2023
Product Development
Kornowski shifts gears at Boston Pharma, sets NASH program as top priority
Ex-Roche exec refines focus, decides what to keep and commercialize vs. what to partner out
BioCentury | Jan 7, 2022
Distillery Therapeutics
Blocking atypical necroptosis in retinal pigment epithelium for AMD
BioCentury | Aug 27, 2021
Distillery Therapeutics
Inhibiting multiple cell death pathways to extend neutrophil shelf life for transfusion
BioCentury | Aug 27, 2021
Distillery Therapeutics
A necroptosis and ferroptosis inhibitor for acute kidney injury
Items per page:
1 - 10 of 46